{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-007420","form_type":"8-K","ticker":"APYX","cik":"0000719135","company_name":"Apyx Medical Corp","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.544786+00:00","generated_at":"2026-05-15T17:18:14.353372+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Apyx Medical Q4 revenue record $19.2M, net loss narrows; FY2026 guidance $57.5-58.5M","bullets":["Q4 total revenue record $19.2M, +34.7% YoY; Surgical Aesthetics +38.1% to $16.7M driven by AYON launch.","Q4 net loss narrowed to $1.3M ($0.03/sh) from $4.6M ($0.12/sh); Adjusted EBITDA $0.7M vs ($2.2M).","FY2025 total revenue $52.8M (+9.9% YoY); net loss $11.2M ($0.27/sh) vs $23.5M ($0.66/sh) in 2024.","FY2026 guidance: total revenue $57.5M-$58.5M; Surgical Aesthetics rev $53M-$54M; OEM rev ~$4.5M.","Submitted 510(k) for AYON power liposuction label expansion; clearance anticipated mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-007420","json":"https://secwatch.observer/filing/0001437749-26-007420.json","markdown":"https://secwatch.observer/filing/0001437749-26-007420.md","text":"https://secwatch.observer/filing/0001437749-26-007420.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/719135/000143774926007420/0001437749-26-007420-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/719135/000143774926007420/apyx20250930_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:18:14.353372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}